Axsome Therapeutics, Inc.
AXSM
$224.03
$7.563.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 63.88% | 65.55% | 65.83% | 69.83% | 72.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.88% | 65.55% | 65.83% | 69.83% | 72.16% |
| Cost of Revenue | 42.45% | 42.56% | 51.37% | 49.27% | 48.33% |
| Gross Profit | 65.88% | 67.72% | 67.25% | 72.04% | 74.77% |
| SG&A Expenses | 46.55% | 38.71% | 33.69% | 23.46% | 24.51% |
| Depreciation & Amortization | 0.00% | -0.27% | -0.27% | -0.30% | -0.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.78% | 26.58% | 29.40% | 27.06% | 35.34% |
| Operating Income | 26.21% | 32.96% | 20.76% | 20.53% | 2.38% |
| Income Before Tax | 32.12% | 36.02% | 25.98% | 19.96% | 6.65% |
| Income Tax Expenses | -723.53% | -723.53% | -169.23% | 12.76% | 105.25% |
| Earnings from Continuing Operations | 32.33% | 36.22% | 26.19% | 19.98% | 6.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.33% | 36.22% | 26.19% | 19.98% | 6.11% |
| EBIT | 26.21% | 32.96% | 20.76% | 20.53% | 2.38% |
| EBITDA | 27.74% | 34.65% | 21.95% | 21.65% | 3.07% |
| EPS Basic | 35.18% | 38.38% | 28.50% | 22.16% | 9.65% |
| Normalized Basic EPS | 29.58% | 34.51% | 21.81% | 20.78% | 5.15% |
| EPS Diluted | 35.18% | 38.38% | 28.50% | 22.16% | 9.65% |
| Normalized Diluted EPS | 29.58% | 34.51% | 21.81% | 20.78% | 5.15% |
| Average Basic Shares Outstanding | 4.23% | 3.82% | 3.38% | 2.95% | 4.11% |
| Average Diluted Shares Outstanding | 4.23% | 3.82% | 3.38% | 2.95% | 4.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |